Cargando…
Yu Ping Feng San Exert Anti-Angiogenesis Effects through the Inhibition of TSLP-STAT3 Signaling Pathways in Hepatocellular Carcinoma
BACKGROUND: Clinically, Yu ping feng san (YPFS) has been extensively used as a medication for treating immune deficiency, and YPFS is combined with chemotherapy drugs to treat cancer, including hepatocellular carcinoma (HCC), lung cancer, and pancreatic cancer. Previous research has shown that YPFS...
Autores principales: | Yuan, Qin, Yao, Fei, Zhou, Liang, Liang, Guoqiang, Song, Xiudao, Jiang, Guorong, Zhou, Man, Zhang, Lurong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6925680/ https://www.ncbi.nlm.nih.gov/pubmed/31885639 http://dx.doi.org/10.1155/2019/1947156 |
Ejemplares similares
-
Screening Active Components from Yu-Ping-Feng-San for Regulating Initiative Key Factors in Allergic Sensitization
por: Shen, Dandan, et al.
Publicado: (2014) -
Mechanism of YuPingFeng in the Treatment of COPD Based on Network Pharmacology
por: Yin, Yunhong, et al.
Publicado: (2020) -
Yupingfeng Granule Improves Th2-Biased Immune State in Microenvironment of Hepatocellular Carcinoma through TSLP-DC-OX40L Pathway
por: Yao, Fei, et al.
Publicado: (2020) -
Anti-inflammatory effect of Yu-Ping-Feng-San via TGF-β1 signaling suppression in rat model of COPD
por: Yang, Zhong-Shan, et al.
Publicado: (2016) -
Yu ping feng san for pediatric allergic rhinitis: A systematic review and meta-analysis of randomized controlled trials
por: Liao, Yong, et al.
Publicado: (2021)